Discovery of quinazoline-benzothiazole derivatives as novel potent protease-activated receptor 4 antagonists with improved pharmacokinetics and low bleeding liability.

MLA

Li, Shanshan, et al. “Discovery of Quinazoline-Benzothiazole Derivatives as Novel Potent Protease-Activated Receptor 4 Antagonists with Improved Pharmacokinetics and Low Bleeding Liability.” European Journal of Medicinal Chemistry, vol. 280, Dec. 2024, p. 116980. EBSCOhost, https://doi.org/10.1016/j.ejmech.2024.116980.

APA

Li, S., Liu, S., Yuan, D., Liu, R., Hu, L., & Zhu, X. (2024). Discovery of quinazoline-benzothiazole derivatives as novel potent protease-activated receptor 4 antagonists with improved pharmacokinetics and low bleeding liability. European Journal of Medicinal Chemistry, 280, 116980. https://doi.org/10.1016/j.ejmech.2024.116980

Chicago

Li, Shanshan, Shangde Liu, Duo Yuan, Renjie Liu, Lifang Hu, and Xiong Zhu. 2024. “Discovery of Quinazoline-Benzothiazole Derivatives as Novel Potent Protease-Activated Receptor 4 Antagonists with Improved Pharmacokinetics and Low Bleeding Liability.” European Journal of Medicinal Chemistry 280 (December): 116980. doi:10.1016/j.ejmech.2024.116980.